Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board
09 Dicembre 2019 - 05:40PM
Saint-Herblain (France), December 9, 2019 –
Valneva SE (“Valneva” or “the Company”) today announced the
appointment of two leading vaccine experts to its Scientific
Advisory Board (SAB). Dr. Stanley A. Plotkin, MD and Dr. Anna
Durbin, MD, have joined Valneva’s SAB.
Dr. Stanley Plotkin serves as a
consultant to the vaccine industry and is an emeritus professor at
both the Wistar Institute and University of Pennsylvania. He
developed the rubella vaccine, which is now used worldwide, and has
played a pivotal role in both the development and application of
various other vaccines including polio, rabies, varicella,
rotavirus and cytomegalovirus. He is the author of more than 800
research papers and has edited several books including the textbook
Vaccines. Dr. Plotkin has served as the senior assistant surgeon
with the Epidemic Intelligence Service, U.S. Public Health Service,
director of the division of infectious diseases at Children’s
Hospital of Philadelphia, associate Chairman of the department of
pediatrics at the University of Pennsylvania and Medical Director
at Sanofi Pasteur for seven years.
Dr. Anna Durbin is a professor
of international health at Johns Hopkins University’s Bloomberg
School of Public Health with a joint appointment in the School of
Medicine. She is trained in Internal Medicine and Infectious
Diseases. Dr. Durbin joined the Center for Immunization Research in
1999 as a Principal Investigator conducting clinical trials for
live attenuated flavivirus vaccines. She has expertise in the
evaluation of a variety of vaccines, including dengue, West Nile
and malaria. Dr. Durbin has served on national and international
advisory boards and committees related to dengue and malaria
vaccine safety, as well as the JHSPH Institutional Review Board.
Dr. Durbin received the NIH Merit Award for outstanding basic and
translational research in developing vaccines for the prevention of
respiratory virus and flavivirus diseases, the NIH Director’s Award
and the Vaccine Industry Excellence Award for Best Academic
Research Team.
Thomas Lingelbach, Chief Executive
Officer of Valneva commented, “Dr. Plotkin and Dr. Durbin
will bring significant expertise to our SAB. We are looking forward
to working with our six SAB members whose highly complementary
skills and external perspectives will be very valuable in informing
our R&D strategy as we move forward.”
Chaired by Dr. Ralf Clemens, Valneva’s SAB
includes Dr. Stanley Plotkin and Dr. Anna Durbin, as well as Dr.
Norman Baylor, Dr. George Siber and Dr. Alain Munoz who were
appointed earlier in 2019.
About Valneva SE
Valneva is a biotech company developing and
commercializing vaccines for infectious diseases with major unmet
needs. Valneva’s portfolio includes two commercial vaccines for
travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various clinical-stage vaccines in
development including unique vaccines against Lyme disease and
chikungunya. Valneva has operations in Austria, Sweden, the United
Kingdom, France, Canada and the US with approximately 490
employees. More information is available at www.valneva.com.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2019_12_09_VLA_SAB_Appointments_PR_EN_Final